MEA Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Middle East and Africa lung cancer diagnostics market is projected to register a substantial CAGR of 9.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030

Market Segmentation:

Middle East and Africa Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Middle East and Africa lung cancer diagnostics market are:

Rise in prevalence and incidence of lung cancer

Increase in healthcare expenditure on cancer diagnosis and treatment

Market Players:

Some of the major players operating in the Middle East and Africa lung cancer diagnostics market are:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific Inc.

Abbott

Quest Diagnostics Incorporated

Bio-Rad Laboratories, Inc.

Biocartis

Danaher

DiaSorin S.p.A

LalPathLabs.com

NanoString

PerkinElmer Inc.

QIAGEN

Siemens Healthcare GmbH

1 INTRODUCTION 52

1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET 52
1.4 LIMITATIONS 54
1.5 MARKETS COVERED 54

2 MARKET SEGMENTATION 57

2.1 MARKETS COVERED 57
2.2 GEOGRAPHICAL SCOPE 58
2.3 YEARS CONSIDERED FOR THE STUDY 59
2.4 CURRENCY AND PRICING 59
2.5 DBMR TRIPOD DATA VALIDATION MODEL 60
2.6 MULTIVARIATE MODELLING 63
2.7 PRODUCT TYPE LIFELINE CURVE 63
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.9 DBMR MARKET POSITION GRID 66
2.10 MARKET TESTING TYPE COVERAGE GRID 68
2.11 VENDOR SHARE ANALYSIS 69
2.12 SECONDARY SOURCES 70
2.13 ASSUMPTIONS 70

3 EXECUTIVE SUMMARY 71

4 PREMIUM INSIGHTS 74

4.1 PORTER'S FIVE FORCES 75
4.2 PESTEL ANALYSIS 76
4.3 INDUSTRY INSIGHTS 77

5 EPIDERMIOLOGY 78

6 REGULATIONS 79

7 MARKET OVERVIEW 82

7.1 DRIVERS 84
- 7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 84
- 7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER 85
- 7.1.3 INCREASING CASES OF LUNG CANCER 87
- 7.1.4 RISE IN PRODUCT APPROVALS 87
7.2 RESTRAINTS 89
- 7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER 89
- 7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY 89
7.3 OPPORTUNITIES 91
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 91
- 7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 91
- 7.3.3 RISING AWARENESS OF LUNG CANCER 92
7.4 CHALLENGES 93
- 7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 93
- 7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
- 7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94

8 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 95

8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
- 8.2.1 IMAGING INSTRUMENTS 100
  - 8.2.1.1 CT SYSTEMS 100
  - 8.2.1.2 ULTRASOUND SYSTEMS 100
  - 8.2.1.3 MRI SYSTEMS 100
  - 8.2.1.4 OTHERS 100
- 8.2.2 BIOPSY INSTRUMENTS 101
  - 8.2.2.1 NEEDLE BIOPSY 101
  - 8.2.2.2 ENDOSCOPIC BIOPSY 101
  - 8.2.2.3 CORE BIOPSY 101
  - 8.2.2.4 OTHERS 101
- 8.2.3 PATHOLOGY-BASED INSTRUMENTS 102
  - 8.2.3.1 SLIDE STAINING SYSTEMS 102
  - 8.2.3.2 TISSUE PROCESSING SYSTEMS 102
  - 8.2.3.3 CELL PROCESSORS 102
  - 8.2.3.4 PCR INSTRUMENTS 102
  - 8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS 102
8.3 CONSUMABLES AND ACCESSORIES 103
- 8.3.1 KITS 104
  - 8.3.1.1 DNA POLYMERASE KITS 104
  - 8.3.1.2 NUCLEIC ACID ISOLATION KITS 104
  - 8.3.1.3 PCR KITS 104
  - 8.3.1.4 OTHERS 104
- 8.3.2 REAGENTS 105
  - 8.3.2.1 ASSAYS 105
  - 8.3.2.2 BUFFERS 105
  - 8.3.2.3 PRIMERS 105
  - 8.3.2.4 OTHERS 105
- 8.3.3 PROBES 106
- 8.3.4 OTHER CONSUMABLES 106

9 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE 107

9.1 OVERVIEW 108
9.2 IMAGING TEST 111
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 112
- 9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 112
- 9.2.3 CHEST X-RAY 112
- 9.2.4 BONE SCAN 112
- 9.2.5 MRI 112
- 9.2.6 OTHERS 112
9.3 BIOMARKERS TEST 113
- 9.3.1 EGFR MUTATION TEST 114
- 9.3.2 KRAS MUTATION TEST 114
- 9.3.3 ALK TEST 114
- 9.3.4 HER2 TEST 114
- 9.3.5 OTHERS 115
9.4 BIOPSY 115
- 9.4.1 NEEDLE BIOPSY 116
- 9.4.2 BRONCHOSCOPY BIOPSY 116
- 9.4.3 CORE BIOPSY 116
- 9.4.4 OTHERS 116
9.5 BLOOD TEST 116
- 9.5.1 COMPLETE BLOOD COUNT (CBC) 117
- 9.5.2 BLOOD CHEMISTRY TESTS 117
- 9.5.3 OTHERS 117
9.6 OTHERS 118

10 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119

10.1 OVERVIEW 120
10.2 NON-SMALL CELL LUNG CANCER 123
10.3 SMALL CELL LUNG CANCER 124

11 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER 125

11.1 OVERVIEW 126
11.2 HOSPITAL 129
11.3 ASSOCIATED LABS 129
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES 130
11.5 DIAGNOSTIC IMAGING CENTERS 131
11.6 CANCER RESEARCH INSTITUTES 131
11.7 OTHERS 132

12 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 133

12.1 OVERVIEW 134
12.2 DIRECT TENDER 137
12.3 RETAIL SALES 138

13 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY REGION 139

13.1 MIDDLE EAST AND AFRICA 140
- 13.1.1 SOUTH AFRICA 150
- 13.1.2 EGYPT 155
- 13.1.3 SAUDI ARABIA 160
- 13.1.4 U.A.E. 165
- 13.1.5 KUWAIT 170
- 13.1.6 OMAN 175
- 13.1.7 BAHRAIN 180
- 13.1.8 QATAR 185
- 13.1.9 REST OF MIDDLE EAST AND AFRICA 190

14 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 191

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 191

15 SWOT ANALYSIS 192

16 COMPANY PROFILE 193

16.1 F. HOFFMANN-LA ROCHE LTD. (2022) 193
- 16.1.1 COMPANY SNAPSHOT 193
- 16.1.2 REVENUE ANALYSIS 193
- 16.1.3 COMPANY SHARE ANALYSIS 194
- 16.1.4 PRODUCT PORTFOLIO 194
- 16.1.5 RECENT DEVELOPMENTS 194
16.2 THERMO FISHER SCIENTIFIC INC. (2022) 195
- 16.2.1 COMPANY SNAPSHOT 195
- 16.2.2 REVENUE ANALYSIS 195
- 16.2.3 COMPANY SHARE ANALYSIS 196
- 16.2.4 PRODUCT PORTFOLIO 196
- 16.2.5 RECENT DEVELOPMENTS 196
16.3 ABBOTT (2022) 197
- 16.3.1 COMPANY SNAPSHOT 197
- 16.3.2 REVENUE ANALYSIS 197
- 16.3.3 COMPANY SHARE ANALYSIS 198
- 16.3.4 PRODUCT PORTFOLIO 198
- 16.3.5 RECENT DEVELOPMENTS 198
16.4 QUEST DIAGNOSTICS INCORPORATED (2022) 199
- 16.4.1 COMPANY SNAPSHOT 199
- 16.4.2 REVENUE ANALYSIS 199
- 16.4.3 COMPANY SHARE ANALYSIS 200
- 16.4.4 PRODUCT PORTFOLIO 200
- 16.4.5 RECENT DEVELOPMENTS 202
16.5 BIODESIX (2022) 203
- 16.5.1 COMPANY PROFILE 203
- 16.5.2 REVENUE ANALYSIS 203
- 16.5.3 COMPANY SHARE ANALYSIS 204
- 16.5.4 PRODUCT PORTFOLIO 204
- 16.5.5 RECENT DEVELOPMENTS 204
16.6 AMOY DIAGNOSTICS CO., LTD. (2022) 205
- 16.6.1 COMPANY SNAPSHOT 205
- 16.6.2 PRODUCT PORTFOLIO 205
- 16.6.3 RECENT DEVELOPMENTS 205
16.7 BIO-RAD LABORATORIES, INC. (2022) 206
- 16.7.1 COMPANY SNAPSHOT 206
- 16.7.2 REVENUE ANALYSIS 206
- 16.7.3 PRODUCT PORTFOLIO 207
- 16.7.4 RECENT DEVELOPMENTS 207
16.8 BIOCARTIS (2022) 208
- 16.8.1 COMPANY SNAPSHOT 208
- 16.8.2 REVENUE ANALYSIS 208
- 16.8.3 PRODUCT PORTFOLIO 209
- 16.8.4 RECENT DEVELOPMENTS 209
16.9 BODITECH MED INC. 210
- 16.9.1 COMPANY PROFILE 210
- 16.9.2 PRODUCT PORTFOLIO 210
- 16.9.3 RECENT DEVELOPMENTS 210
16.10 DANAHER (2022) 211
- 16.10.1 COMPANY SNAPSHOT 211
- 16.10.2 REVENUE ANALYSIS 211
- 16.10.3 PRODUCT PORTFOLIO 212
- 16.10.4 RECENT DEVELOPMENTS 212
16.11 DIASORIN S.P.A. (2022) 213
- 16.11.1 COMPANY SNAPSHOT 213
- 16.11.2 REVENUE ANALYSIS 213
- 16.11.3 PRODUCT PORTFOLIO 214
- 16.11.4 RECENT DEVELOPMENTS 214
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022) 215
- 16.12.1 COMPANY SNAPSHOT 215
- 16.12.2 REVENUE ANALYSIS 215
- 16.12.3 PRODUCT PORTFOLIO 216
- 16.12.4 RECENT DEVELOPMENTS 216
16.13 20/20 GENE SYSTEMS 217
- 16.13.1 COMPANY PROFILE 217
- 16.13.2 PRODUCT PORTFOLIO 217
- 16.13.3 RECENT DEVELOPMENTS 217
16.14 GUARDANT HEALTH INC. 218
- 16.14.1 COMPANY PROFILE 218
- 16.14.2 PRODUCT PORTFOLIO 218
- 16.14.3 RECENT DEVELOPMENTS 218
16.15 INIVATA LTD. 219
- 16.15.1 COMPANY PROFILE 219
- 16.15.2 PRODUCT PORTFOLIO 219
- 16.15.3 RECENT DEVELOPMENTS 219
16.16 LALPATHLABS.COM (2022) 220
- 16.16.1 COMPANY SNAPSHOT 220
- 16.16.2 REVENUE ANALYSIS 220
- 16.16.3 PRODUCT PORTFOLIO 221
- 16.16.4 RECENT DEVELOPMENTS 222
16.17 LUNGLIFE AI, INC. (2022) 223
- 16.17.1 COMPANY SNAPSHOT 223
- 16.17.2 PRODUCT PORTFOLIO 223
- 16.17.3 RECENT DEVELOPMENTS 223
16.18 MEDGENOME 224
- 16.18.1 COMPANY SNAPSHOT 224
- 16.18.2 PRODUCT PORTFOLIO 224
- 16.18.3 RECENT DEVELOPMENTS 225
16.19 MYRIAD GENETICS, INC. 226
- 16.19.1 COMPANY SNAPSHOT 226
- 16.19.2 PRODUCT PORTFOLIO 226
- 16.19.3 RECENT DEVELOPMENTS 226
16.20 NEOGENOMICS LABORATORIES (2022) 227
- 16.20.1 COMPANY SNAPSHOT 227
- 16.20.2 REVENUE ANALYSIS 227
- 16.20.3 PRODUCT PORTFOLIO 228
- 16.20.4 RECENT DEVELOPMENTS 228
16.21 NANOSTRING (2022) 229
- 16.21.1 COMPANY SNAPSHOT 229
- 16.21.2 REVENUE ANALYSIS 229
- 16.21.3 PRODUCT PORTFOLIO 230
- 16.21.4 RECENT DEVELOPMENTS 230
16.22 NANOENTEK 231
- 16.22.1 COMPANY PROFILE 231
- 16.22.2 PRODUCT PORTFOLIO 231
- 16.22.3 RECENT DEVELOPMENTS 231
16.23 ONCOCYTE CORPORATION 232
- 16.23.1 COMPANY PROFILE 232
- 16.23.2 SERVICE PORTFOLIO 232
- 16.23.3 RECENT DEVELOPMENTS 232
16.24 PERKINELMER INC 233
- 16.24.1 COMPANY PROFILE 233
- 16.24.2 REVENUE ANALYSIS 233
- 16.24.3 PRODUCT PORTFOLIO 234
- 16.24.4 RECENT DEVELOPMENTS 234
16.25 PLEXBIO 235
- 16.25.1 COMPANY SNAPSHOT 235
- 16.25.2 PRODUCT PORTFOLIO 235
- 16.25.3 RECENT DEVELOPMENTS 235

16.26 QIAGEN 236
- 16.26.1 COMPANY SNAPSHOT 236
- 16.26.2 REVENUE ANALYSIS 236
- 16.26.3 PRODUCT PORTFOLIO 237
- 16.26.4 RECENT DEVELOPMENTS 237
16.27 SIEMENS HEALTHCARE GMBH 238
- 16.27.1 COMPANY SNAPSHOT 238
- 16.27.2 REVENUE ANALYSIS 238
- 16.27.3 PRODUCT PORTFOLIO 239
- 16.27.4 RECENT DEVELOPMENTS 239
16.28 VERACYTE, INC. (2022) 240
- 16.28.1 COMPANY SNAPSHOT 240
- 16.28.2 REVENUE ANALYSIS 240
- 16.28.3 PRODUCT PORTFOLIO 241
- 16.28.4 RECENT DEVELOPMENTS 241
16.29 VELA DIAGNOSTICS 242
- 16.29.1 COMPANY PROFILE 242
- 16.29.2 PRODUCT PORTFOLIO 242
- 16.29.3 RECENT DEVELOPMENTS 244

17 QUESTIONNAIRE 245

18 RELATED REPORTS 248

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 27
FIGURE 2 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 30
FIGURE 3 MIDDLE EAST & AFRICA LUNGS CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 31
FIGURE 4 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 32
FIGURE 5 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 32
FIGURE 6 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 35
FIGURE 7 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 36
FIGURE 8 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 38
FIGURE 9 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 39
FIGURE 10 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 43
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT LUNG CANCER IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD 44
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET IN 2023 & 2030 44
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET 53
FIGURE 14 THE MIDDLE EAST & AFRICA MORTALITY RATE DUE TO CANCER 56
FIGURE 15 THE DATA GIVEN BELOW SHOWS THE INCREASING MIDDLE EAST & AFRICA CANCER RATE IN 2020 56
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT 59
FIGURE 17 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 66
FIGURE 18 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 67
FIGURE 19 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 67
FIGURE 20 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 68
FIGURE 21 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 78
FIGURE 22 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 79
FIGURE 23 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 79
FIGURE 24 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 80
FIGURE 25 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 90
FIGURE 26 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 91
FIGURE 27 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 91
FIGURE 28 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 92
FIGURE 29 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2022 96
FIGURE 30 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 97
FIGURE 31 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 97
FIGURE 32 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 98
FIGURE 33 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 104
FIGURE 34 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 105
FIGURE 35 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 105
FIGURE 36 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 106
FIGURE 37 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 111
FIGURE 38 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 112
FIGURE 39 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 112
FIGURE 40 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 113
FIGURE 41 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 113
FIGURE 42 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 161